Clinical Trials Directory

Trials / Completed

CompletedNCT00122018

An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery

N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
80 (planned)
Sponsor
Linda F. Barr, M.D. · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients with abnormal kidney function are at increased risk for complications following heart surgery, including worsening kidney function possibly requiring dialysis, a prolonged stay in the critical care unit and hospital, and the increased risk of death. Prior attempts at kidney protection for heart surgery patients have had mixed results. Two medicines, fenoldopam and N-acetylcysteine, have been shown to protect kidney function in other circumstances that cause kidney stress. The purpose of this study is to determine whether these medications will help to maintain the function of diseased kidneys during heart surgery.

Detailed description

This is a randomized, double-blinded, placebo-controlled trial to evaluate fenoldopam and N-acetylcysteine (NAC) individually, and together, as renal protective agents for patients with renal insufficiency undergoing heart surgery. Subjects have chronic renal insufficiency with creatinine clearance (CrCl) \</= 40cc/min but not on pre-operative dialysis, and receive: NAC 600 mg by mouth (po) twice a day (bid) or placebo starting 24 hours pre-operative and continuing through the day of surgery; and/or fenoldopam 0.1 mcg/kg/min intravenous (IV) or saline placebo at anesthetic induction and continuing for 48 hours. Outcome data include: nadir, post-operative day 3 and post-operative day 14 CrCl, time to CrCl nadir, length of Intensive Care Unit (ICU) stay, length of post-operative hospital stay, hospital costs, mortality, and the need for hemodialysis. Intraoperative and post-operative pressor use is being monitored. The enrollment will include 80 patients (20 in each group).

Conditions

Interventions

TypeNameDescription
DRUGN-acetylcysteine
DRUGfenoldopam

Timeline

Start date
2002-05-01
Primary completion
2006-03-01
Completion
2006-03-01
First posted
2005-07-21
Last updated
2014-11-07

Source: ClinicalTrials.gov record NCT00122018. Inclusion in this directory is not an endorsement.

An Investigation of N-acetylcysteine and Fenoldopam as Renal Protection Agents for Cardiac Surgery (NCT00122018) · Clinical Trials Directory